Tendie Bot

Tendie.bot

Login
FEMY Articles
reddit/

FEMY Stands Out on r/pennystocks as Long-Term Bet on Non-Surgical Birth Control

FEMY (Femasys Inc.) ranked 9th on Tendie.bot's daily ticker ranking on October 9, 2025, propelled by a high-engagement Reddit post on r/pennystocks that argued the stock is a long-term pick due to its innovative non-surgical permanent birth control product, FemBloc. The post highlighted the science, market opportunity, and ongoing Phase 3 trial. No same-day news catalysts were observed, making the interest entirely community-driven.

  1. FEMY ranked 9th on Tendie.bot's daily ticker ranking with 8 posts, 80 comments, and 120 upvotes, reflecting strong retail interest.

  2. A highly detailed post on r/pennystocks argued that

    FEMY
    $FEMY is a long-term pick based on its non-surgical permanent birth control product FemBloc and its market potential.

  3. No same-day news catalysts were detected; the discussion was entirely community-driven.

On October 9, 2025,

FEMY
$FEMY emerged as a notable topic among retail investors on r/pennystocks, ranking 9th on Tendie.bot's daily ticker leaderboard with a sharp upward movement of 13 spots. The ticker gathered 8 dedicated posts, 80 comments, and 120 upvotes, indicating concentrated conversation despite its micro-cap status.

Why Reddit Is Focused on FEMY

The primary driver was a detailed post titled "Why $FEMY is a longterm pick" that received 47 upvotes and 48 comments. The author, who claimed prior success with

SHOT
$SHOT, laid out a thesis centered on Femasys' lead product, FemBloc — a non-surgical permanent birth control procedure that uses a balloon catheter to deliver a biomaterial that blocks the fallopian tubes. The post emphasized that approximately 13% of U.S. women may opt for permanent contraception, yet the only FDA-approved surgical option is tubal ligation. FemBloc, currently in a Phase 3 clinical trial (NCT04273594 / CP-100-008) with estimated completion by April 2027, could offer a less invasive alternative with minimal side effects.

Market Opportunity and Community Sentiment

The post highlighted FEMY's low market cap ($25–35 million) and small float as characteristics that could amplify moves if the product thesis gains traction. Commenters engaged on the science, the timeline to approval, and the potential partnership landscape. Sentiment was notably positive, with a Tendie.bot sentiment score of 0.5375, reflecting a bullish lean among the discussion participants. No negative posts or major skepticism were present in the sampled data.

Without any same-day news headlines to explain the sudden attention, the surge in discussion appears to have been fueled entirely by the organic reach of this single post and the community's appetite for early-stage biotech stories. The rank_delta of +13 suggests that FEMY was not previously on retail investors' radars but quickly captured interest once the thesis was laid out.

Subscribe to Tendie.bot for more market recaps.